Save up to 90% on Kanjinti with Coupons, Discount Cards & Patient Assistance Programs

Kanjinti is the brand name for trastuzumab-ann subcutaneous injection and IV infusion.

Kanjinti is available as 150 mg and 420 mg used for injection.

Kanjinti is a monoclonal antibody that is used to treat:

• HER2-positive, breast cancers – IV and SQ injections
• HER2-positive, metastatic stomach cancer – IV injection only

Kanjinti is a monoclonal antibody that acts as a human epidermal growth factor receptor 2 (HER2) inhibitor. It blocks a specific protein in the body that’s important for cell growth called HER2. HER2 is found on both normal and cancer cells. Cancer cells usually have more HER2 proteins than normal cells. This can cause cancer cells to grow more quickly than normal cells. When HER2 is blocked by Kanjinti, cancer cells can’t grow and spread as well.

Kanjinti dose for IV infusion is based on weight and given over 30 to 90 minutes. The dose for a subcutaneous injection is not based on weight.

Kanjinti is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you.

Common side effects of Kanjinti:

• Body and joint pain
• Weakness
• Fever
• Nausea
• Chills
• Headache
• Cough
• Diarrhea
• Vomiting
• Infection

Serious side effects are rare with Kanjinti. Contact your healthcare provider immediately if you experience any of the following.

• Heart problems: chest pain, racing heartbeat, shortness of breath that usually worsens with activity or while lying flat, swelling of your legs or feet, sudden weight gain, fatigue
• Serious infusion reactions: trouble breathing, itching or hives, flushing, swelling, chest pain, fast heartbeat, dizziness, fainting
• Lung problems: shortness of breath, trouble breathing
  Serious infections (when receiving in combination with chemotherapy): repeated fevers, chills, sweating, cough, trouble breathing, severe diarrhea, vomiting, painful or frequent urination

The following medications may interact with Kanjinti:

• Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of Kanjinti’s long washout period based. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Kanjinti products
• If anthracyclines are used, the patient’s cardiac function should be monitored carefully

Amgen Inc.

Kanjinti can cause fetal harm when administered to a pregnant woman. Pregnant women and females of reproductive that take Kanjinti during pregnancy or within 7 months prior to conception can result in fetal harm. Contact your healthcare provider with a known or suspected pregnancy. Females who can become pregnant should use effective contraception during treatment and for 7 months following the last dose of Kanjinti.

• Trastuzumab-ANNS